Skip to main content

Table 3 Trend test and dose-dependent effect of the intensity of PPAR-γ modulating treatments on risk of recurrent ischemic stroke by using the whole cohort before matching

From: Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study

Trend

Patient number

No. of event (%)

p trend

p trend‡

Trend test of telmisartan and pioglitazone effect

0.087

0.076

 Pioglitazone plus telmisartan

246

42 (17.1)

  

 Pioglitazone alone

2944

556 (18.9)

  

 Telmisartan alone

2259

490 (21.7)

  

Dose-dependent effect of pioglitazone

0.015

0.068

 MPR ≥ 80

1406

231 (16.4)

  

 MPR < 80

1784

367 (20.6)

  

 Non-pioglitazone

32,645

6973 (21.4)

  
  1. PPAR-γ peroxisome proliferator-activated receptor-gamma, MPR medication possession ratio
  2. Statistical significance was set at p < 0.05
  3. ‡Adjusted for all the variables listed in Table 1, except medications, follow-up years and the propensity score
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840